Supplements

Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with  Immune Checkpoint Inhibitors

Best Practices: Biomarkers and Treatment Selection in the Management of Advanced NSCLC

2022 Midyear Review: Non–Small-Cell Lung Cancer

First-Line Treatment of Metastatic Non-small cell Lung Cancer (NSCLC)

First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy
Lung cancer is the second-most common type of cancer in the United States, including approximately 235,000 new cases each year, 84% of which are non–small-cell lung cancer (NSCLC). Read More ›

Best Practices in Multiple Myeloma: Improving Adherence to Optimize Patient Outcomes

First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

2021 Year in Review - Multiple Myeloma

February 2022 Clinical Trials to Clinical Practice

Page 1 of 6


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: